Home | Find A Doctor | Contact Us

 

Phase II Trial of Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed By Campath-1H For Previously Treated Relapsed or Refractory Patients With Chronic Lymphocytic Leukemia


Principal Investigator: Sanford Kempin, MD
Time frame of study: Ongoing
Location of Study:

Mount Sinai Beth Israel
St.Luke's-Mount Sinai Roosevelt

Contact:

Continuum Cancer Research Program
(212) 844-6286

 

Summary:
This study aims to evaluate the objective response rate of pentostatin, cyclophosphamide, and rituximab (PCR) in patients with previously treated B-cell chronic lymphocytic leukemia (CLL), and to assess the presence of minimal residual disease (MRD) at the completion of the treatment regimen and after Campath-1H in patients who achieve a complete remission or nodular partial remission.


Eligibility and Treatment Plan:
• Age = 18 years
• Previously treated relapsed or refractory Chronic Lymphocytic Leukemia (CLL)
• Patients must not have had previous CAMPATH-1H therapy prior to entering the study;
• Women must not be pregnant or breast feeding

Please call for more information.

 

 

Privacy Policy | Site Map
Copyright ©  Icahn School of Medicine at Mount Sinai | Mount Sinai Health System